Residence time measurements obtained by serial whole-body conjugate-view imaging are
commonly used in patient-specific dosimetry for radioimmunotherapy applications. In order …

131I-Tositumomab has been used in treating patients with non-Hodgkin's lymphoma. It is
generally recommended that high-energy collimators be used to image patients before they …

A methodology was developed determining patient releasability after radioimmunotherapy
with tositumomab and 131I-tositumomab for the treatment of non-Hodgkin's lymphoma …

A 3-dimensional (3D) imaging–based patient-specific dosimetry methodology incorporating
antitumor biologic effects using biologically effective dose (BED) and equivalent uniform …

The tositumomab/131I-tositumomab radioimmunotherapy regimen is administered as a
dosimetric dose followed by a therapeutic dose. The biodistribution of the dosimetric dose is …

Estimating organ residence times is an essential part of patient‐specific dosimetry for
radioimmunotherapy (RIT). Quantitative imaging methods for RIT are often evaluated using …

For optimal treatment planning in radionuclide therapy, robust tumor dose–response
correlations must be established. Here, fully 3-dimensional (3D) dosimetry was performed …

High-dose 90Y-ibritumomab tiuxetan therapy and associated autologous stem cell
transplantation (ASCT) were applied after dosimetry. This paper reports dosimetric findings …

The study aimed at identifying patient-specific dosimetric and nondosimetric factors
predicting outcome of non-Hodgkin lymphoma patients after 131I-tositumomab …

This study describes the use of a new method for correcting count losses due to deadtime in
the context of quantitative imaging of patients undergoing scintigraphy after a 4 GBq …